142 related articles for article (PubMed ID: 24307330)
21. Modeling disease-state transition heterogeneity through Bayesian variable selection.
Healy BC; Engler D
Stat Med; 2009 Apr; 28(9):1353-68. PubMed ID: 19206077
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials.
Aoyama T; Kashiwabara K; Oba K; Honda M; Sadahiro S; Hamada C; Maeda H; Mayanagi S; Kanda M; Sakamoto J; Saji S; Yoshikawa T
Cancer Med; 2017 Nov; 6(11):2523-2530. PubMed ID: 28948714
[TBL] [Abstract][Full Text] [Related]
23. Bayesian mixed hidden Markov models: a multi-level approach to modeling categorical outcomes with differential misclassification.
Zhang Y; Berhane K
Stat Med; 2014 Apr; 33(8):1395-408. PubMed ID: 24254432
[TBL] [Abstract][Full Text] [Related]
24. Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
Fadelu T; Zhang S; Niedzwiecki D; Ye X; Saltz LB; Mayer RJ; Mowat RB; Whittom R; Hantel A; Benson AB; Atienza DM; Messino M; Kindler HL; Venook A; Ogino S; Ng K; Wu K; Willett W; Giovannucci E; Meyerhardt J; Bao Y; Fuchs CS
J Clin Oncol; 2018 Apr; 36(11):1112-1120. PubMed ID: 29489429
[TBL] [Abstract][Full Text] [Related]
25. Hazard regression model and cure rate model in colon cancer relative survival trends: are they telling the same story?
Bejan-Angoulvant T; Bouvier AM; Bossard N; Belot A; Jooste V; Launoy G; Remontet L
Eur J Epidemiol; 2008; 23(4):251-9. PubMed ID: 18264781
[TBL] [Abstract][Full Text] [Related]
26. A Bayesian method for construction of Markov models to describe dynamics on various time-scales.
Rains EK; Andersen HC
J Chem Phys; 2010 Oct; 133(14):144113. PubMed ID: 20949993
[TBL] [Abstract][Full Text] [Related]
27. Bayesian random threshold estimation in a Cox proportional hazards cure model.
Zhao L; Feng D; Bellile EL; Taylor JM
Stat Med; 2014 Feb; 33(4):650-61. PubMed ID: 24009083
[TBL] [Abstract][Full Text] [Related]
28. Real-time individual predictions of prostate cancer recurrence using joint models.
Taylor JM; Park Y; Ankerst DP; Proust-Lima C; Williams S; Kestin L; Bae K; Pickles T; Sandler H
Biometrics; 2013 Mar; 69(1):206-13. PubMed ID: 23379600
[TBL] [Abstract][Full Text] [Related]
29. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
30. Incorporation of nested frailties into semiparametric multi-state models.
Rotolo F; Rondeau V; Legrand C
Stat Med; 2016 Feb; 35(4):609-21. PubMed ID: 26381148
[TBL] [Abstract][Full Text] [Related]
31. Identifying influential observations in Bayesian models by using Markov chain Monte Carlo.
Jackson D; White IR; Carpenter J
Stat Med; 2012 May; 31(11-12):1238-48. PubMed ID: 21905065
[TBL] [Abstract][Full Text] [Related]
32. Bayesian measurement-error-driven hidden Markov regression model for calibrating the effect of covariates on multistate outcomes: Application to androgenetic alopecia.
Yen AM; Chen HH
Stat Med; 2018 Sep; 37(21):3125-3146. PubMed ID: 29785802
[TBL] [Abstract][Full Text] [Related]
33. The single-index/Cox mixture cure model.
Amico M; Van Keilegom I; Legrand C
Biometrics; 2019 Jun; 75(2):452-462. PubMed ID: 30430553
[TBL] [Abstract][Full Text] [Related]
34. Recurrence and cancer-specific death after adjuvant chemotherapy for Stage III colon cancer.
Chapuis PH; Bokey E; Chan C; Keshava A; Rickard MJFX; Stewart P; Young CJ; Dent OF
Colorectal Dis; 2019 Feb; 21(2):164-173. PubMed ID: 30253025
[TBL] [Abstract][Full Text] [Related]
35. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
Jordan P; Brunschwig H; Luedin E
Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
[TBL] [Abstract][Full Text] [Related]
36. A new threshold regression model for survival data with a cure fraction.
Kim S; Chen MH; Dey DK
Lifetime Data Anal; 2011 Jan; 17(1):101-22. PubMed ID: 20414804
[TBL] [Abstract][Full Text] [Related]
37. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Meyerhardt JA; Heseltine D; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Thomas J; Nelson H; Whittom R; Hantel A; Schilsky RL; Fuchs CS
J Clin Oncol; 2006 Aug; 24(22):3535-41. PubMed ID: 16822843
[TBL] [Abstract][Full Text] [Related]
38. Mutation, cell kinetics, and subpopulations at risk for colon cancer in the United States.
Herrero-Jimenez P; Thilly G; Southam PJ; Tomita-Mitchell A; Morgenthaler S; Furth EE; Thilly WG
Mutat Res; 1998 May; 400(1-2):553-78. PubMed ID: 9685710
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
[TBL] [Abstract][Full Text] [Related]
40. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
Pauler DK; Finkelstein DM
Stat Med; 2002 Dec; 21(24):3897-911. PubMed ID: 12483774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
